New FDA Nod Boosts Philips, Masimo Partnership

Philips and Masimo have earned U.S. Food and Drug Administration (FDA) clearance to allow SedLine brain function monitoring, Regional Oximetry (O3), and CO2 measurements in Philips patient monitors IntelliVue MX750 and MX850.
 
Integrating the advanced Masimo measurements into Philips IntelliVue MX series multi-parameter monitors can help assess and monitor blood saturation in the brain, anesthetic sedation, and patient respiratory performance with the same monitor. Data can also be shared between monitors.
 
“Our work with Masimo has enabled us to forge new paths in continuous monitoring,” Christoph Pedain, GM of Hospital Patient Monitoring at Philips told the press. “We’re connecting data and technologies to help arm care providers with the robust information they need to make timely, informed care decisions for their patients.”
 
“Combining our expertise in noninvasive monitoring and signal processing technologies with Philips’ expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike,” added Jon Coleman, president of worldwide OEM sales and global health, Masimo. “We are proud that Philips has chosen to make our innovative SedLine, O3, and NomoLine technologies available to their customers. We look forward to continuing our partnership with a focus on improving patient outcomes and reducing the cost of care.”
 
Philips and Masimo first began their partnership in 2016. Since then, they have introduced a variety of advanced monitoring capabilities to select IntelliVue MX-series monitors.